ArticleBlood2024

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.

Warren Fiskus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.